ALK-positive anaplastic large cell lymphoma with dic(2;4)(p23;q33)

Leukemia Research

Volumn 33, Issue 6, 2009, Pages

  Niitsu, Nozomi ^a   Kohri, Mika ^a   Hayama, Miyuki ^b   Tamaru, Jun ichi ^c   Miura, Ikuo ^d  

^a International Medical Center   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; VINCRISTINE;

ADULT; ANAMNESIS; CANCER REGRESSION; CASE REPORT; CHROMOSOME ABERRATION; CLINICAL FEATURE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LARGE CELL LYMPHOMA; LETTER; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 4; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 63349092726     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.038     Document Type: Letter

References (12)

1. Gascoyne R.D., Aoun P., Wu D., et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93 (1999) 3913-3921
2. Falini B., Pulford K., Pucciarini A., et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 94 (1999) 3509-3515
3. Shiota M., Nakamura S., Ichinohasama R., et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86 (1999) 1954-1960
4. Pittaluga S., Wlodarska I., Pulford K., et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 151 (1997) 343-351
5. Wlodarska I., De Wolf-Peeters C., Falini B., et al. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood 92 (1998) 2688-2695
6. Ott G., Katzenberger T., Siebert R., et al. Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas. Genes Chromosomes Cancer 22 (1998) 114-121
7. Rosenwald A., Ott G., Pulford K., et al. t(1;2)(q21;p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood 94 (1999) 362-364
8. Liang X., Meech S.J., Odom L.F., et al. Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol 121 (2004) 496-506
9. Niitsu N., Okamoto M., Aoki S., et al. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Haematol 85 (2006) 374-380
10. Pulford K., Lamant L., Espinos E., et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 61 (2004) 2939-2953
11. Stein H., Foss H.D., Dürkop H., et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96 (2000) 3681-3695
12. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004